Predictive Technology Group, Inc. · OTC:PREDQ
Predictive Technology — Investor Presentation (December 2018)
32 slides from Predictive Technology's investor presentation, Dec 4, 2018
Slide 1: December 4, 2018
December 4, 2018 OTC: PRED predtechgroup.com
Slide 2: Safe Harbor
Safe Harbor This presentation contains forward-looking statements. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends," "estimates," "plans," "pote
Slide 3: Vision Statement
Vision Statement Improving lives through data analytics, diagnostics and precision biopharmaceutical solutions. 2
Slide 4: Company Overview – Operates Three Subsidiaries
Company Overview – Operates Three Subsidiaries • Develops and commercializes • Develops and commercializes • Secures procurement of tissue novel genetic-based regenerative human tissue, for Predictive Biotech products diagnostics and therapeutics human cell and cellular products • Biorepository of D
Slide 5: Predictive Technology Group Management Team
Predictive Technology Group Management Team Name Title John Sorrentino PRED – Chairman Pfizer - COO, Pediatrics, Vaccines, R&D Bradley Robinson Chief Executive Officer Simon Brewer Chief Financial Officer Tim Lacy Chief Revenue Officer Paul Evans Chief Operations Officer Michael Herbert Chief Market
Slide 6: Predictive Technology Group Advisory Board
Predictive Technology Group Advisory Board Name Title Ronald Barhorst ING Financial - CEO (retired 2014) Hugh S. Taylor, M.D. Yale School of Medicine New Haven Hospital - Professor and Chair, Department of Obstetrics, Gynecology and Reproductive Sciences. Jonas Cedergren Managing Director - JC Capit
Slide 7: Investment Highlights
Investment Highlights • Proven management team with success from R&D, to operations and commercialization • First product line - internally developed Human Cell and Tissue Products - launched in 2017 with ongoing, strong revenue growth that has established PRED as the industry leader • Expect to lau
Slide 8: Growth Drivers
Growth Drivers • Continued expansion of existing human cell and tissue lines • Allograft sales in 2017 exceed 10,000 and 2018 YTD exceed 37,000 • 2X 2017 allograft sales in first eight months of 2018 • +47,000 allografts used in human patients de-risk product development as allograft results predict
Slide 9: Advanced regenerative medicine products that enhance the body's natural ability to heal
Advanced regenerative medicine products that enhance the body’s natural ability to heal and augment current therapies
Slide 10: 2018 Strong Revenue Growth - Cell and Tissue Products
2018 Strong Revenue Growth - Cell and Tissue Products 2017 and 2018 Sales Actual vs Forecast Year end: June 30 • Revenue growth 9,000,000 continues to 2018 FY Q1 Q2 Q3 Q4 FY accelerate 8,000,000 Actual $2.2 $3.2 $4.2 $7.2 $16.8 • Every quarter to 7,000,000 date exceeded Forecast $1.2 $2.0 $3.2 $4.0
Slide 11: Overview
Overview Predictive Biotech was established to: • Provide advanced regenerative medicine products • Enhance the body’s natural ability to heal • Augment and co-administration to current therapies • Develop cell and tissue processing platform What is Regenerative Medicine? • Regenerative medicine is
Slide 12: How does Regenerative Medicine Work?
How does Regenerative Medicine Work? As our bodies age, we experience: Building Blocks: • Longer healing times • Over time, healthy tissue can become • Increased inflammation dysfunctional due to age and injury. A • Changing chemical environment human cell and tissue product (HCT/P) is • Cell exhaus
Slide 13: Product Portfolio
Product Portfolio CoreCyte”™ Cord Tissue Allograft Suspension CoreCyte™ is a minimally manipulated human tissue allograft suspension derived from the Wharton's Jelly of the umbilical cord. CoreCyte™ is processed to preserve the biological and structural integrity of Wharton's jelly for homologous us
Slide 14: Procurement and Process
Procurement and Process CLEAN BIRTH > COLLECTION > MOTHER > + Tissue is sanitized and cleaned prior to processing + Donated tissues are collected and shipped ‘overnight for processing at our laboratory + All donated tissues are procured and collected after full-term, live births + Donors (mother and
Slide 15: Improving lives through data analytics, diagnostics and precision biopharmaceutical solutions
Improving lives through data analytics, diagnostics and precision biopharmaceutical solutions.
Slide 16: Research and Development Platform Assets
Research and Development Platform Assets • Library of 300,000 DNA samples with genetic birth defect or serious maternity issue • HIPAA compliant • Collected from most genetically diverse population in the U.S. • Believed to be the world’s largest DNA library related to women’s health • Proprietary g
Slide 17: What is Endometriosis?
What is Endometriosis? • A painful disorder in which tissue that normally lines the inside the uterus — the endometrium — grows outside the uterus. • Affects 1 in 10 women during their reproductive years* • 27 million symptomatic women in U.S. • 176 million women worldwide • 30-50% of women with end
Slide 18: Problem #1: Endometriosis Underlying Infertility
Problem #1: Endometriosis Underlying Infertility • 25-50% of infertile women have endometriosis* • IVF complications are greater in women with active endometriosis • Increased risk of adverse pregnancy outcomes in women with endometriosis • Evidence-based diagnosis for endometriosis was accompanied
Slide 19: Solution: Suite of Endometriosis and Infertility Tests
Solution: Suite of Endometriosis and Infertility Tests Diagnostic Test ARTGuide® Non-invasive diagnostic test for endometriosis and other genetic causes of infertility. Indicated for the 1 in 8 women with infertility and leads to better decision making regarding IVF and other treatments Fertility Dx
Slide 20: The ARTguide Test
The ARTguide™ Test 700 DNA Markers + 5 Clinical Predictors + Established Fertility Markers = A Definitive Tool which Optimizes and Individualizes Advanced Fertility Care 19
Slide 21: ARTguide Test Report Features
ARTguide™ Test Report Features A precision medicine tool that is clinically validated to predict a woman’s risk of Endometriosis Assay Description Infertility Gene Panel Results Endometriosis Risk * Based on research at the time of product launch, the Endometriosis Risk for the ARTguide Test is only
Slide 22: ARTguide 11-Gene Fertility Panel
ARTguide™ 11-Gene Fertility Panel Gene Symbol Gene Name Condition(s) FOXL2 Forkhead Box L2 Primary Ovarian Insufficiency Ovarian Dysgenesis 1, Ovarian Hyperstimulation Syndrome, Ovarian Response to FSH FSHR Follicle Stimulating Hormone Receptor Stimulation LHB Luteinizing Hormone Beta Polypeptide Hy
Slide 23: Revolution: Results
Revolution: Results • Results • 712 damaging mutations validated • 9 genes with multiple mutations • 77 independent markers implicated in endometriosis GWAS studies • 11-gene panel with 81 damaging variants associated with infertility 22
Slide 24: ARTGuide: Test Development
ARTGuide®: Test Development • Endometriosis R&D based on: • >30,000 endometriosis patients • >100,000 sequenced population controls • Validation • Comprehensive 2 phase GWAS discovery • 3,000 exomes sequenced to detect low frequency variants • >1,000 useful markers patented • Independent training co
Slide 25: ARTGuide Test
ARTGuide® Test • 3 classes of markers • SNP (70 SNPs) • SNP (1,300 mutations) • Sequencing (10 genes) • Integrating genetic risk with clinical criteria achieves >90% Area Under Receiver Operator Characteristic Curve (ROC) Run on Next Gen Sequencer • >1,400 endometriosis markers • Human genes • 4 cli
Slide 26: ARTGuide & Fertility Dx Commercialization
ARTGuide® & Fertility Dx® Commercialization First Products to Market • Efficient sales to large, yet highly concentrated market • 480 assisted reproduction technology (ART) clinics in the U.S.; 80% of market in 6 metro regions • Self-pay test with no reliance on reimbursement • 8-10 sales representa
Slide 27: Problem #2: Endometriosis and Chronic Pain
Problem #2: Endometriosis and Chronic Pain • Abnormal tumors cause bleeding, ”To be honest, ENDO scarring and inflammation ruins my life…it robs • Endometriosis can cause chronic, me of days each debilitating pelvic pain month…I am at my • No reliable laboratory test wits end with this • Healthcare
Slide 28: Solution: ENDORisk and NHP-07 Therapeutic
Solution: ENDORisk® and NHP-07 Therapeutic Diagnostic - ENDORisk® Therapeutic – NHP-07 • Predictive genetic test for • Proprietary therapeutic for endometriosis covered by key endometriosis prevention and/or issued and pending patents suppression • Incorporates proprietary • Can be administered prio
Slide 29: Competitive Landscape
Competitive Landscape • No competitors for predictive DNA endometriosis test • Small company has developed CNV markers • Immunologic, protein, gene expression, miRNA test, endometrial biopsy, CT scan tests under development • Accelerating pharma interest in endometriosis • AbbVie received FDA approv
Slide 30: Product Pipeline in Spine Disorders
Product Pipeline in Spine Disorders • Current diagnostic methods are invasive and expensive • Need for diagnostic to determine course of care for better outcomes • Need for payers to better determine the risk of the insured population • Scoliosis Diagnostic Test • Proprietary genetic-based test pred
Slide 31: Predictive Consolidated Financial Highlights
Predictive Consolidated Financial Highlights FYE FYE Q1 FYE FYE in 000s Q1 20193 Change Change 20183 20173 20183 20173 20163 $ $ $ $ Revenue $8,064 543.1% $2,055 3346.7% 16,624 2,585 2,585 75 GP % 72.8% 76.1% 70.9% 7.3% 66.0% 70.9% 0.0% 100.0% R&D % 7.5% 11.4% 3.3% 245.5% 0.1% 3.3% 1.3% 153.8% Sales
Slide 32: In Summary
In Summary • Proven management team with success from R&D, to operations and commercialization • First product line - internally developed Human Cell and Tissue Products - launched in 2017 with ongoing, strong revenue growth that has established PRED as the industry leader • Expect to launch 2 novel
Predictive Technology Group — Investor Presentation (December 2018) on 6ix